Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
Adaptimmune, a biotech company focused on the use of engineered T cells to treat cancer, has announced the full-time appointment of James Noble as chief executive officer. 26 March 2014
German pharma and chemical major Merck KGaA has announced the promotion of three distinguished internal managers to head the life-science-tools and consumer health divisions as well as its allergy business unit. 26 March 2014
Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) has announced the appointment of Giles Platford as Head of Commercial Operations, Emerging Markets. 19 March 2014
UK-based company NeRRe Therapeutics, which is focused on the development of neurokinin (NK) receptor antagonists for a range of indications, has announced the appointment of Ian Nicholson as Chief Business Officer (CBO). 19 March 2014
Spherix Incorporated (NASDAQ: SPEX) have announced that Frank Reiner has joined the company as vice president of
licensing, where he will report to chief executive Anthony Hayes and play a key role in the company's licensing efforts. 19 March 2014
Avion Pharmaceuticals, a US-based specialty pharmaceutical company, has announced the promotion of Mike Sullivan to the position of president. 18 March 2014
Australian product development company Clinical Network Services (CNS) has launched a new UK office headed by Paul Cronin who joins as UK Director and Director, Business Development. 10 March 2014
US headquartered Moderna Therapeutics, a leader in the development of RNA (mRNA) Therapeutics has announced that Lorence Kim will join Moderna's executive leadership team as chief financial officer, effective April 21. 7 March 2014
Aquavit Pharmaceuticals, a private US-based life science company, has announced the appointment of David Goldberg as chief medical officer. 6 March 2014
French biopharmaceutical company Genticel has recruited Sophie Olivier as chief medical officer to lead the clinical development of its pipeline, in particular the ProCervix Phase II trial. 4 March 2014
Australian biotech company Novogen has announced the appointments of new board members and a strategic advisor to support its transition into a clinical-stage company with a growing US presence and an investor base in the USA and Australia. 4 March 2014
Executives are moving back to an ‘ex-directory’ world, where smaller, restricted networks are of the highest value, according to RSA, a global life sciences executive search and interim management specialist. 3 March 2014
Australian biotechnology firm Phosphagenics has appointed biotech industry veterans Lawrence Gozlan, Nathan Drona and Geert Cauwenbergh as non-executive directors, with Mr Gozlan assuming the role of Chairman of the Board on an interim basis. 3 March 2014
Belgium’s largest drugmaker, UCB, yesterday announced a succession plan for its chief excecutive, Roch Doliveux, saying that Jean-Christophe Tellier, currently executive vice president, Biopharma Brands and Solutions, will be appointed chief executive-elect and chairman of the executive committee as of March 1, 2014. 21 February 2014
Germany’s Merck KGaA has appointed Simon Sturge to head the biosimilars unit, effective March 1, succeeding Thierry Hulot, who created the biosimilars unit and took over responsibility for Global Manufacturing & Supply for the Merck Serono division at the end of last year. 20 February 2014